Penwest Pharmaceuticals (PPCO) Inactive 10-Q2010 Q1 Quarterly report

Filed: 10 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Good

New words: Alvogen, analyzing, apparent, Asian, biochemical, chronic, chronically, CII, committee, commonly, compensatory, conclusion, counterclaim, country, cut, debilitating, degenerative, disaggregate, discernible, disclaim, disorder, DOJ, enacted, enterprise, Europe, expansion, fast, FDC, forfeit, found, GSE, HCl, hire, impose, IRB, justify, laboratory, lose, Medicaid, minimum, neurodegenerative, notification, Obama, President, produce, progressive, putting, rebate, Reconciliation, reform, repayment, Retention, reversal, reverse, Roxane, satisfaction, substantive, tentative, Topic, track, treble, undertaken, unfair, unfunded, unreasonably, view, voluntary, Watson, withhold

Removed: abbreviated, adequately, advancing, alleging, analgesic, asset, assign, assume, biological, body, breakeven, carrying, cautioned, cell, chemical, clarify, closer, concept, conform, controlling, convince, Cosmetic, covenant, disclose, Dist, energy, enhancing, entity, exclude, executing, factor, fall, Hatch, improve, inclusion, infrastructure, intent, intrinsic, Investigational, launched, legitimate, literature, Maximizing, measure, mitochondria, molecule, Monetizing, NJ, notify, notifying, null, offsetting, onForm, operate, opportunity, par, periodically, profile, pronouncement, proof, properly, prosecute, protecting, proven, purpose, reassigned, receivable, reclassified, refiling, refused, reinstate, renewing, replacement, rescinded, rescue, reserve, resolution, served, sized, solicitation, solid, Specialty, stake, strong, sue, suffering, targeted, test, traded, underway, void, Waxman, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PPCO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(b) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350

In connection with the Quarterly Report on Form 10-Q of Penwest Pharmaceuticals Co. (the “Company”) for the period ended March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jennifer L. Good, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: May 10, 2010	/s/ Jennifer L. Good
	Jennifer L. Good
	President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)